ARS Pharma’s Neffy The First Needle-Free Epinephrine Nasal Spray Now Available Across U.S.

ARS Pharmaceuticals has officially launched neffy®, its FDA-approved epinephrine nasal spray, now available by prescription across the U.S. The product is approved for emergency treatment of Type I allergic reactions, including anaphylaxis, in children aged four and older who weigh between 15 and <30 kilograms (33 to <66 pounds). Approved in March 2025, Neffy is the first needle-free alternative to traditional epinephrine auto-injectors for this age group.

Eric Karas, Chief Commercial Officer of ARS Pharma, stated, “Many children fear needles, which can lead parents to delay administering needle-based epinephrine treatments. This delay may result in serious consequences. The availability of the 1 mg dose before summer travel, camps, and back-to-school season will help communities better prepare for allergic emergencies. The needle-free design of Neffy also eliminates the risk of adverse events, such as accidental injections into the hands or fingers of a child or caregiver, which happens about 3,500 times each year. Now is a great time for parents to contact their healthcare providers to ask for Neffy as a treatment for their young children.”

Designed with portability and ease-of-use in mind, Neffy fits easily into a backpack or lunchbox. In human factor studies, all participants successfully used the nasal spray by following instructions, outperforming the up to 35% error rates seen with injection devices. The product also has a robust shelf life of 24 months and can withstand heat up to 122°F for up to three months. If frozen accidentally, Neffy can be thawed and used without losing quality.

“We’ve been focused on working with leading national insurance companies to ensure that Neffy is readily available to patients. We are making great progress with United Healthcare, Express Scripts, OptumRx and others, recognising the value of neffy, and we anticipate expanding commercial coverage over the summer so people can get neffy without restrictions or additional paperwork from physicians. We believe this will give young patients and caregivers greater peace of mind as they head into the new school year,” says Richard Lowenthal, Co-Founder, President, and CEO of ARS Pharma. 

To ensure wide access, ARS Pharma is offering comprehensive support programs, including co-pay assistance and a Patient Assistance Program for eligible uninsured or underinsured individuals. Through a savings program, commercially insured patients can receive two single-use devices for no more than $25, while the retail cash price for two doses is $199 via GoodRx. These affordability options aim to ensure that Neffy is accessible in homes, schools, and care settings where allergic emergencies may occur.

“The expanded availability of EpiPen represents real progress for our community, especially for young children who may be more likely to speak up about symptoms of a serious allergic reaction when they know epinephrine can be given without a needle. This news means more families will have options that help them be ready to act and administer ‘Epi first, Epi fast’ when a reaction occurs, when every second counts. We commend ARS Pharma for its commitment to innovation, access, and the prioritisation of the needs of patients with severe food allergy,” said Sung Poblete, PhD, RN, CEO of FARE (Food Allergy Research & Education), the leading nonprofit organisation dedicated to food allergy.